Further investigation revealed that this interesting phenomenon may be related to R-2HG, a metabolite of IDH, compound 39 (R-2HG, FTO IC50 = 133.3 μM) (Fig. 12A) can affect the FTO/m6A/MYC/CEBPA pathway and inhibit tumor proliferation and survival by repressing the expression of FTO. Here, CEBPA is linked to neoplasm.